HKeyBio

HKeyBio is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation small molecule therapies for cancer. The company utilizes its proprietary HKey discovery platform to target critical biological nodes in DNA damage response and protein homeostasis pathways. Its lead candidate, HKB-101, is a potent and selective USP1 inhibitor currently in Phase 1/2 clinical development for patients with advanced solid tumors, particularly those harboring homologous recombination deficiencies. Headquartered in the San Francisco Bay Area with significant operations in China, HKeyBio integrates global resources to accelerate the delivery of precision medicines. The leadership team comprises industry veterans with extensive experience in global drug development from major pharmaceutical companies.